ArticleJournal of gastrointestinal oncology2026
Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) overexpression/ Methods: We conducted a retrospective single-center cohort study including patients with localized gastric or GEJ adenocarcinoma who underwent curative-intent surgery between 2017 and 2021. HER2 status was assessed on PTB and matched SS using immunohistochemistry (IHC) with reflex in situ hybridization (ISH) for IHC-2+ cases, according to gastric cancer guidelines. Concordance between PTB and SS, the impact of biopsy sampling adequacy, and dynamic changes in HER2 status following neoadjuvant therapy were analyzed descriptively. Results: Fifty-seven patients were included. Median age was 67 years; 77% were male. Neoadjuvant treatment was administered in 89.5% of patients, while 10.5% underwent upfront surgery. HER2 positivity was observed in 21.1% of biopsies and 15.8% of SS. Overall concordance of HER2 status between PTB and SS was 87.7% [95% confidence interval (CI): 76.3-94.9%]. Seven discordant cases were identified, including five cases of HER2 loss (biopsy-positive/resection-negative) and two cases of HER2 gain. Among the 12 tumors initially classified as HER2-positive on biopsy, HER2 positivity was maintained in seven cases (58.3%) but lost in five (41.7%; 95% CI: 15.2-72.3%). When restricted to patients receiving neoadjuvant therapy, HER2 loss occurred in 5 of 10 HER2-positive cases (50.0%; 95% CI: 18.7-81.3%). Increasing the number of biopsy fragments did not significantly reduce discordance between biopsy and SS. Conclusions: HER2 status shows overall good concordance between diagnostic biopsies and SS in localized gastric and GEJ adenocarcinomas. However, a substantial proportion of initially HER2-positive tumors exhibited loss of HER2 expression following neoadjuvant chemotherapy. These findings suggest that HER2 expression/
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.